Persista Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Persista Bio is pioneering a novel drug delivery platform designed to overcome the major hurdles in cell therapy: immune rejection, cell viability, and patient burden. Its lead program targets Type 1 diabetes with an implant that encapsulates insulin-secreting stem cells and provides them with oxygen, aiming to automatically regulate blood glucose for years. Founded in 2021 and based on licensed technology from Cornell University and Giner, Inc., the company is in the preclinical stage, having demonstrated proof-of-concept in diabetic rat models. Persista Bio's platform is also designed to be translatable to other metabolic and enzyme deficiency disorders.

Type 1 DiabetesMetabolic Disorders

Technology Platform

O2Line™ Oxygenated Encapsulation System: A platform combining an anti-fibrotic macroencapsulation device (to protect cells from immune rejection) with an implantable electrochemical oxygen generator (iEOG) to support high-density, long-term viability of therapeutic cells.

Opportunities

The primary opportunity is to address the vast, underserved Type 1 diabetes market with a potential curative, long-term implant that eliminates daily management.

Secondly, the platform technology is designed to be translatable, enabling partnerships to develop similar implants for other metabolic diseases, enzyme deficiencies, and cell therapy indications, positioning Persista as an enabler for the broader cell therapy industry.

Risk Factors

Key risks include the significant technical and regulatory hurdles of moving from rodent proof-of-concept to a safe, effective, and durable human implant, as the system is a complex combination product.

The company also faces intense competition from other cell encapsulation and automated insulin delivery technologies, and execution risk as a small, seed-stage company dependent on future funding.

Competitive Landscape

Persista Bio competes in the beta-cell replacement space for T1D against companies like Vertex (via acquired islet programs) and ViaCyte (encapsulation devices), and more broadly against advanced automated insulin delivery systems (e.g., from Medtronic, Tandem, Insulet). Its key differentiator is the integrated oxygen generation, which aims to solve the critical cell viability issue that has challenged other encapsulation approaches.

More companies in Drug Delivery & Formulation →More companies in United States →